Ovarian Cancer | Specialty

PARP Inhibitors Move Into the Limelight

August 21st 2015

Research evidence has been mounting that PARP inhibitors are not just for gynecologic malignancies-or for patients whose tumors harbor inherited BRCA defects.

Dr. Kauff on Challenges in Treating Uterine Cancer

August 19th 2015

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.

Lead Researcher Discusses Anti-PD-L1 Agent Avelumab in Ovarian Cancer

August 18th 2015

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian Cancer

August 11th 2015

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

Novel Immunotherapeutic Agent Shows Benefit in Ovarian Cancer

August 10th 2015

Premal H. Thaker, MD, discusses EGEN-001 in combination with pegylated liposomal doxorubicin and the potential of immunotherapy agents in ovarian and other similar cancers.

Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer

July 28th 2015

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Failure to Follow Weight-Based Chemo Guidelines Lowers Survival in Ovarian Cancer

July 23rd 2015

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Dr. Infante on Avelumab's Potential in Ovarian Cancer

July 22nd 2015

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Coleman Explains New Biomarker for PARP Inhibitors in Ovarian Cancer

July 17th 2015

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

FDA Grants Peptide Vaccine Orphan Status for Ovarian Cancer

July 17th 2015

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.

Future of Ovarian and Cervical Cancers

July 2nd 2015

Treating Locally Advanced Cervical Cancer

July 2nd 2015

Prevention and Early Detection of Cervical Cancer

July 2nd 2015

Carboplatin Versus Cisplatin in Cervical Cancer

July 2nd 2015

Bevacizumab in Advanced Cervical Cancer

July 2nd 2015

Managing Platinum-Resistant Ovarian Cancer

July 2nd 2015

Utilizing Olaparib in Ovarian Cancer

July 2nd 2015

Biomarkers for Bevacizumab in Ovarian Cancer

July 2nd 2015

Frontline Therapy in Advanced Ovarian Cancer

July 2nd 2015

Bevacizumab in Platinum-Sensitive Ovarian Cancer

July 2nd 2015